|Bid||0.2652 x 800|
|Ask||0.2700 x 4000|
|Day's range||0.2633 - 0.2867|
|52-week range||0.2080 - 1.9700|
|Beta (5Y monthly)||2.03|
|PE ratio (TTM)||N/A|
|Earnings date||10 Aug 2022 - 15 Aug 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||1.98|
Corbus Pharmaceuticals (CRBP) delivered earnings and revenue surprises of 11.11% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Corcept (CORT) posts overall survival data from a phase II study evaluating relacorilant plus nab-paclitaxel for treating recurrent platinum-resistant ovarian cancer.
Carter's, Target Hospitality, iQIYI, The Buckle, and Corbus Pharmaceuticals are part of today's Screen of the Week blog.